SCHEMBL1685488

SCHEMBL1685488

CC(=Nc1c(F)cccc1F)c1cccc(C(C)=Nc2c(F)cccc2F)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
ACMSD Q8TDX5 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HSP90AA1 P07900 1/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
AGTR1 P30556 2/20 0.34
PKM P14618 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP1A2 P05177 1/20 0.32
MAPT P10636 1/20 0.30
CES2 O00748 1/20 0.30
CES1 P23141 1/20 0.30
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
HKDC1 Q2TB90 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1685486 1.00 KDM4E (0.34) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL5889225 0.98 NPC1 (0.33) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL5713531 0.98 NPC1 (0.33) KDM4EALOX15TSHRACMSDTDP1
Hydrochloric Acid SCHEMBL1685854 0.96 NPC1 (0.35) KDM4EALOX15TSHRACMSDTDP1
Hydrochloric Acid SCHEMBL1685853 0.96 NPC1 (0.35) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL19347668 0.93 NPC1 (0.31) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL5358692 0.92 KDM4E (0.37) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL5358693 0.92 KDM4E (0.37) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL2227999 0.90 ACHE (0.36) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL2228003 0.90 ACHE (0.36) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794691-A1 PROCESS FOR CONTROLLING THE POLYMER COMPOSITION OF AN ETHYLENE COPOLYMER OBTAINED BY A CATALYST SYSTEM COMPRISING A TRANSITION METAL CATALYST COMPONENT AND A ZIEGLER CATALYST COMPONENT Basell Polyolefine GmbH (DE) 2014-10-29 EP disclosed
EP-2655445-A1 PROCESS FOR CONTROLLING THE RELATIVE ACTIVITY OF ACTIVE CENTERS OF CATALYST SYSTEMS COMPRISING AT LEAST ONE LATE TRANSITION METAL CATALYST COMPONENT AND AT LEAST ONE ZIEGLER CATALYST COMPONENT Basell Polyolefine GmbH (DE) 2013-10-30 EP disclosed
WO-2013092453-A1 PROCESS FOR CONTROLLING THE POLYMER COMPOSITION OF AN ETHYLENE COPOLYMER OBTAINED BY A CATALYST SYSTEM COMPRISING A TRANSITION METAL CATALYST COMPONENT AND A ZIEGLER CATALYST COMPONENT BASELL POLYOLEFINE GMBH (DE) 2013-06-27 WO disclosed
WO-2012084774-A1 PROCESS FOR CONTROLLING THE RELATIVE ACTIVITY OF ACTIVE CENTERS OF CATALYST SYSTEMS COMPRISING AT LEAST ONE LATE TRANSITION METAL CATALYST COMPONENT AND AT LEAST ONE ZIEGLER CATALYST COMPONENT BASELL POLYOLEFINE GMBH (DE) 2012-06-28 WO disclosed
EP-2367855-A1 METHOD FOR TRANSITIONING BETWEEN INCOMPATIBLE OLEFIN POLYMERIZATION CATALYST SYSTEMS Basell Polyolefine GmbH (DE) 2011-09-28 EP disclosed
WO-2011089000-A1 PROCESS FOR THE PREPARATION OF ETHYLENE COPOLYMER COMPOSITIONS IN THE PRESENCE OF AN OLIGOMERIZATION CATALYST BASELL POLYOLEFINE GMBH (DE) 2011-07-28 WO disclosed
EP-2328968-A1 POLYETHYLENE FOR INJECTION MOLDINGS Basell Polyolefine GmbH (DE) 2011-06-08 EP disclosed
EP-2303937-A1 METHOD FOR TRANSITIONING BETWEEN INCOMPATIBLE OLEFIN POLYMERIZATION CATALYST SYSTEMS Basell Polyolefine GmbH (DE) 2011-04-06 EP disclosed
WO-2010072367-A1 METHOD FOR TRANSITIONING BETWEEN INCOMPATIBLE OLEFIN POLYMERIZATION CATALYST SYSTEMS BASELL POLYOLEFINE GMBH (DE) 2010-07-01 WO disclosed
WO-2010022941-A1 POLYETHYLENE FOR INJECTION MOLDINGS BASELL POLYOLEFINE GMBH (DE) 2010-03-04 WO disclosed
EP-1294482-B1 LIGANDS AND CATALYST SYSTEMS THEREOF FOR ETHYLENE OLIGOMERISATION TO LINEAR ALPHA OLEFINS SHELL INT RESEARCH (NL) 2005-03-30 EP disclosed
US-20050059786-A1 Process for the co-oligomerisation of ethylene and alpha olefins DE BOER ERIC JOHANNES MARIA (NL) 2005-03-17 US disclosed
US-20050014983-A1 Process for producing linear alpha olefins SHELL OIL COMPANY 2005-01-20 US disclosed
WO-2005005354-A1 PROCESS FOR PRODUCING LINEAR ALPHA OLEFINS SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 2005-01-20 WO disclosed
US-20040116758-A1 Catalyst systems for ethylene oligomerisation to linear alpha olefins SHELL OIL COMPANY 2004-06-17 US disclosed
US-6683187-B2 BIS-ARYLIMINEPYRIDINE COMPLEXES WITH IRON OR COBALT; METHYL ALUMINOXANE COORDINATION CATALYSTS; HIGH YIELD, SELECTIVITY SHELL OIL COMPANY 2004-01-27 US disclosed
EP-1294482-A2 LIGANDS AND CATALYST SYSTEMS THEREOF FOR ETHYLENE OLIGOMERISATION TO LINEAR ALPHA OLEFINS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 2003-03-26 EP disclosed
US-20020128409-A1 Process for the co-oligomerisation of ethylene and alpha olefins SHELL OIL COMPANY 2002-09-12 US disclosed
US-20020028941-A1 Ligands and catalyst systems thereof for ethylene oligomerisation to linear alpha olefins SHELL OIL COMPANY 2002-03-07 US disclosed
WO-2002000339-A2 LIGANDS AND CATALYST SYSTEMS THEREOF FOR ETHYLENE OLIGOMERISATION TO LINEAR ALPHA OLEFINS SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014983-A1 Process for producing linear alpha olefins OXSR1, AP2S1, CBR3 KDM4E 3055/4885ALOX15 201/4885TSHR 621/4885
US-20020028941-A1 Ligands and catalyst systems thereof for ethylene oligomerisation to linear alpha olefins OPRM1, OPRD1, PYM1 KDM4E 2326/4885ALOX15 309/4885TSHR 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.